Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates-Reference-Cited by-同舟云学术

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Published:2016-08 Issue:8 Volume:101 Page:3163-3170
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Miller P. D.,Pannacciulli N.,Brown J. P.,Czerwinski E.,Nedergaard B. S.,Bolognese M. A.,Malouf J.,Bone H. G.,Reginster J.-Y.,Singer A.,Wang C.,Wagman R. B.,Cummings S. R.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of osteoporosis screening in older Swedish women (SUPERB);Bone;2024-10

2. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

3. Comparing the Efficacy of Antiosteoporotic Drugs in Preventing Periprosthetic Bone Loss Following Total Hip Arthroplasty: A Systematic Review and Bayesian Network Meta‐Analysis;Orthopaedic Surgery;2024-07-26

4. Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial;Journal of Clinical Oncology;2024-07-02

5. Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-10